Quantum News
Sign InSign Up
Back to News
research

Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Nektar Therapeutics presented 52-week Phase 2b extension results for rezpegaldesleukin in severe alopecia areata, showing sustained efficacy and safety in long-term treatment during an April 2026 investor call. The REZOLVE-AA trial’s extension period demonstrated durable hair regrowth in patients, with key endpoints met, reinforcing the drug’s potential as a first-in-class IL-2 pathway modulator for autoimmune hair loss. CEO Howard Robin and CMO Mary Tagliaferri highlighted plans for Phase 3 trials, aiming for regulatory submissions, pending further data validation and discussions with health authorities. Dermatology experts, including Dr. Jonathan Silverberg, joined the call to contextualize results, emphasizing unmet needs in alopecia areata and rezpegaldesleukin’s differentiated mechanism versus existing therapies. Analysts from firms like Citigroup and Piper Sandler probed commercialization timelines, market potential, and competitive positioning, signaling strong investor interest in the drug’s future.
AI Audio Summary
0:00 / 0:00
Click to play
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript

Summarize this article with:

ChatGPTChatGPTPerplexityPerplexityClaudeClaudeGrokGrok

SA Transcripts159.37K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata April 20, 2026 8:00 AM EDT Company Participants Vivian Wu - Investor RelationsHoward W. Robin - CEO, President & DirectorJonathan Zalevsky - Senior VP and Chief Research & Development OfficerMary Tagliaferri - Chief Medical Officer Conference Call Participants Jonathan SilverbergDavid RosmarinBenjamin UngarJulian Harrison - BTIG, LLC, Research DivisionSamantha Semenkow - Citigroup Inc., Research DivisionYasmeen Rahimi - Piper Sandler & Co., Research DivisionJay Olson - Oppenheimer & Co. Inc., Research DivisionJiale Song - Jefferies LLC, Research DivisionMayank Mamtani - B. Riley Securities, Inc., Research DivisionMarc Frahm - TD Cowen, Research DivisionYu He - H.C. Wainwright & Co, LLC, Research DivisionYu Fan - Wedbush Securities Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the Nektar Therapeutics Analyst and Investor event to discuss REZOLVE-AA 52-week top line results from the extension treatment period. [Operator Instructions] I will now hand the conference over to Vivian Wu, Investor Relations and Corporate Affairs. Vivian, please go ahead. Vivian WuInvestor Relations Thank you, and good morning, everyone. Thank you for joining us today. Today, you will hear from Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Suski, our Chief Research and Development Officer; and Dr. Mary Tagliaferri, our Chief Medical Officer. We're also joined today by our panel of experts in dermatology and alopecia areata, who will join us in Q&A. Dr. Jonathan Silverberg, Dr. David Rosmarin and Dr. Benjamin Ungar. On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the potential of and future development plans for rezpegaldesleukin. The timing and plans for future clinical data presentations and other statements regarding the future of our business. Because forward-looking statements relate to the future, they are subject

Read Original

Source Information

Source: Seeking Alpha